KMT2E: A Potential Drug Target and Biomarker (G55904)

Target Name: KMT2E

NCBI ID: G55904

KMT2E

KMT2E: A Potential Drug Target and Biomarker

KMT2E (Kidney Mammalian Tissue 2) is a protein that is expressed in the kidney tissue, and it has been found to play a significant role in the development and progression of a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The study of KMT2E and its potential as a drug target or biomarker has gained significant attention in recent years, and this article will explore its potential as well as its current status in the scientific community.

Current Research on KMT2E

KMT2E has been shown to be involved in a number of different biological processes in the body, including cell signaling, inflammation, and autophagy. Several studies have investigated the role of KMT2E in these processes, and have found that it plays a crucial role in the development and progression of a variety of diseases.

One of the most significant findings related to KMT2E is its role in the development of cancer. Several studies have shown that KMT2E is highly expressed in a variety of cancer types, including breast, lung, and ovarian cancer. Additionally, studies have found that KMT2E is involved in the development of cancer by promoting the growth and survival of cancer cells, as well as by inhibiting the death of cancer cells.

Another area of research related to KMT2E is its role in neurodegenerative diseases. Several studies have shown that KMT2E is involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Additionally, studies have found that KMT2E is involved in the destruction of nerve cells, which is a hallmark feature of neurodegenerative diseases.

In addition to its role in cancer and neurodegenerative diseases, KMT2E has also been shown to be involved in autoimmune disorders. Several studies have shown that KMT2E is involved in the development and progression of autoimmune disorders, including rheumatoid arthritis and multiple sclerosis.

Potential Therapeutic Applications

The potential therapeutic applications for KMT2E are vast, and there is significant interest in using it as a drug target or biomarker in a variety of diseases. One of the most promising areas of research is the use of KMT2E as a drug target for cancer. Several studies have shown that KMT2E is involved in the development and progression of cancer, and that targeting it may be an effective way to treat these diseases.

In addition to its potential as a drug target, KMT2E has also been shown to be a potential biomarker for a variety of diseases. Its expression has been shown in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Additionally, studies have shown that KMT2E is involved in the development and progression of these diseases, which suggests that it may be a useful biomarker for identifying the early stages of these diseases.

Current Status of KMT2E Research

KMT2E is a protein that has been shown to play a significant role in a variety of biological processes in the body, including cell signaling, inflammation, and autophagy. Several studies have investigated the role of KMT2E in these processes, and have found that it plays a crucial role in the development and progression of a variety of diseases.

The most significant finding related to KMT2E is its role in the development of cancer. Several studies have shown that KMT2E is highly expressed in a variety of cancer types, including breast, lung, and ovarian cancer. Additionally, studies have found that KMT2E is involved in the development of cancer by promoting the growth and survival of cancer cells, as well as by inhibiting the death of cancer cells.

Another area of research related to KMT2E is its role in neurodegenerative diseases. Several studies have shown that KMT2E is involved in the development and progression of

Protein Name: Lysine Methyltransferase 2E (inactive)

Functions: Associates with chromatin regions downstream of transcriptional start sites of active genes and thus regulates gene transcription (PubMed:23629655, PubMed:24130829, PubMed:23798402). Chromatin interaction is mediated via the binding to tri-methylated histone H3 at 'Lys-4' (H3K4me3) (PubMed:24130829, PubMed:23798402). Key regulator of hematopoiesis involved in terminal myeloid differentiation and in the regulation of hematopoietic stem cell (HSCs) self-renewal by a mechanism that involves DNA methylation (By similarity). Also acts as an important cell cycle regulator, participating in cell cycle regulatory network machinery at multiple cell cycle stages including G1/S transition, S phase progression and mitotic entry (PubMed:14718661, PubMed:18573682, PubMed:19264965, PubMed:23629655). Recruited to E2F1 responsive promoters by HCFC1 where it stimulates tri-methylation of histone H3 at 'Lys-4' and transcriptional activation and thereby facilitates G1 to S phase transition (PubMed:23629655). During myoblast differentiation, required to suppress inappropriate expression of S-phase-promoting genes and maintain expression of determination genes in quiescent cells (By similarity)

The "KMT2E Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KMT2E comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets